Abstract
Iproniazid and several other hydrazine inhibitors of the oxidative deamination of brain catecholamines and indoleamines were the first drugs shown to be effective in the treatment of major depressive disorders. Although iproniazid itself proved to be hepatotoxic and is no longer used clinically, and the tricyclic antidepressants came to be regarded as safer and more broadly effective drugs, other monoamine oxidase (MAO) inhibitors continue to be widely used, especially in tricyclicresistant depressed patients.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Further reading
Beckmann H, Riederer P, eds (1983): Monoamine Oxidase and Its Selective Inhibitors: New Concepts in Therapy and Research. Basel: Karger
Murphy DL, Garrick NA, Cohen RM (1983): Monoamine oxidase inhibitors and monoamine oxidase: Biochemical and physiological aspects relevant to human psychopharmacology. In: Drugs in Psychiatry, Vol 1, Antidepressants, Burrows JD, Norman TR, Davies E, eds. Amsterdam: Elsevier/North Holland Biomedical Press
Squires RF (1978): Monoamine oxidase inhibitors: Animal pharmacology. In: Handbook of Psychopharmacology, Vol 14, Iverson LL, Iversen SD, Snyder SH, eds. New York: Plenum Press
Tipton KF, Dostert P, Strolin Benedetti M, eds (1984): Monoamine Oxidase and Disease. London: Academic Press
Rights and permissions
Copyright information
© 1989 Springer Science+Business Media New York
About this chapter
Cite this chapter
Murphy, D.L. (1989). Monoamine Oxidase (MAO) Inhibitors in Psychiatric Therapy. In: Abnormal States of Brain and Mind. Readings from the Encyclopedia of Neuroscience . Birkhäuser, Boston, MA. https://doi.org/10.1007/978-1-4899-6768-8_33
Download citation
DOI: https://doi.org/10.1007/978-1-4899-6768-8_33
Publisher Name: Birkhäuser, Boston, MA
Print ISBN: 978-1-4899-6770-1
Online ISBN: 978-1-4899-6768-8
eBook Packages: Springer Book Archive